JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Agilent Technologies (NYSE:A) Stock

Agilent Technologies (NYSE:A) had its price target hoisted by JPMorgan Chase & Co. from $165.00 to $180.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 16.49% from the company’s previous close.

A has been the subject of several other research reports. Barclays upped their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a report on Wednesday, October 8th. Evercore ISI lifted their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research note on Tuesday, October 7th. Rothschild Redb upgraded shares of Agilent Technologies to a “strong-buy” rating in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and an average target price of $161.08.

Agilent Technologies Trading Down 1.7%

Shares of A stock opened at $154.52 on Tuesday. The stock has a market cap of $43.81 billion, a P/E ratio of 36.27, a price-to-earnings-growth ratio of 4.67 and a beta of 1.29. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $160.27. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The stock has a 50 day simple moving average of $141.36 and a 200 day simple moving average of $126.23.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.01. The firm had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $1.46 EPS. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. On average, research analysts predict that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 911 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total value of $130,491.64. Following the completion of the transaction, the chief executive officer directly owned 32,058 shares of the company’s stock, valued at approximately $4,591,987.92. This trade represents a 2.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds have recently bought and sold shares of the company. CIBC Bancorp USA Inc. bought a new stake in shares of Agilent Technologies during the 3rd quarter worth $5,030,000. Center For Asset Management LLC purchased a new stake in Agilent Technologies during the third quarter valued at about $234,000. Captrust Financial Advisors lifted its stake in Agilent Technologies by 2.4% during the third quarter. Captrust Financial Advisors now owns 43,179 shares of the medical research company’s stock worth $5,542,000 after purchasing an additional 1,021 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in shares of Agilent Technologies by 16.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 5,640 shares of the medical research company’s stock worth $724,000 after purchasing an additional 813 shares in the last quarter. Finally, Danske Bank A S bought a new position in shares of Agilent Technologies during the 3rd quarter valued at about $51,528,000. Hedge funds and other institutional investors own 87.41% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.